Friday, February 22, 2019 10:20:26 AM
The evidence is stacking up that disrupted sleep is causally linked with the progression of AD, in part due to increased neuronal activity during wakefulness. Does this imply that dampening down synaptic activity could be beneficial in AD by preventing tau release and spread? Probably not, because strong epidemiologic evidence indicates that promoting neural activity through higher levels of education and exercise reduces the risk of developing AD ( Display footnote number: 11 ). Engaging in activities that provide external stimuli is thought to boost cognitive reserve by building robust networks that are more resilient to diverse insults. However, it is possible that brain networks that are active by default in the absence of external input, and that are known to be dysregulated in AD, could be targeted to slow pathological protein accumulation ( Display footnote number: 12 ).
The benefits of sleep have previously been linked with AD in the context of toxic aggregate clearance, including via the glymphatic system. This pathway, which is most active during sleep, allows exchange of proteins between ISF and CSF and their clearance into perivascular spaces and the lymphatic system ( Display footnote number: 9 ). Damage to molecular and cellular components of the glymphatic system during aging, in the course of neurodegenerative disease, and following physical brain trauma is closely linked with the increased presence of tau and Aß in extracellular fluids, the spread of aggregated proteins (including tau) in the brain, and worsened cognition ( Display footnote number: 13, 14 ).
The contribution of astrocytes, an intrinsic component of the glymphatic system, during AD sleep disruption is also of interest. The astrocyte-neuron lactate shuttle responds to increased energy demands of excitatory neurons during wakefulness, increasing lactate release for conversion to glutamate in neurons ( Display footnote number: 5 ). Sleep disruption in AD will affect astrocyte-directed effects on synaptic activity–driven tau release as well as on tau clearance mechanisms.
Sleep deprivation therefore results in abnormal synaptic activity that increases tau release into extracellular spaces, at times when its clearance is impaired by reduced CSF and ISF flow. If this results in the retention of tau species that are able to seed aggregation, tau pathology will spread across the brain, leading to progressive synapse and neuron dysfunction (see the figure). For those at risk of developing AD, treatments to promote sleep, including those already under investigation for Parkinson’s disease ( Display footnote number: 15 ), may have great benefit. The best advice for everyone is to do all we can to maintain a healthy life balance, sleep well, and engage with activities to keep the body and mind healthy.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM

